Inhibrx Inks Potential $500M Antibody License with Celgene
Just two years after its launch, privately held Inhibrx LLC hooked Celgene Corp. in its first antibody license. The deal for the undisclosed target potentially could exceed $500 million, including up-front, clinical and regulatory milestone payments and royalties on commercial sales.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter